Esperion Launches New Scientific Website
24 févr. 2023 13h40 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 24, 2023 (GLOBE NEWSWIRE) -- With a focus on science and clinical evidence, Esperion today announced the launch of the website, esperionscience.com. This website, geared...
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
11 janv. 2023 11h00 HE
|
Esperion Therapeutics, Inc.
CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement...
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
08 janv. 2023 19h00 HE
|
Esperion Therapeutics, Inc.
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive...
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
19 déc. 2022 16h15 HE
|
Esperion Therapeutics, Inc.
– Positive CLEAR Outcomes data to be presented as a Late-Breaking Clinical Trial (LBCT) at ACC.23/WCC on March 4, 2023 – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral...
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
07 déc. 2022 08h05 HE
|
Esperion Therapeutics, Inc.
– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse...
Esperion Appoints Ben Halladay Chief Financial Officer
16 nov. 2022 16h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior...
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
09 nov. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline,...
Esperion to Participate in Jefferies London Healthcare Conference
02 nov. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on...
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
01 nov. 2022 07h00 HE
|
Esperion Therapeutics, Inc.
– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be...
Esperion Hosting Virtual Research & Development Day
27 oct. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion...